Xenon Stock Jumps On New Encouraging Data From Epilepsy Treatment

Xenon Pharmaceuticals Inc XENE announced additional positive data from new sub-analyses of Phase 2b X-TOLE trial of XEN1101 in adult patients with focal epilepsy. The Data will be presented at the Annual Meeting of the American Epilepsy Society.

• Additional primary and secondary measures included a pairwise comparison of each active dose to placebo and a responder analysis. 
• Related Link: Xenon Pharma Shares Jump After Epilepsy Treatment Phase 2 Data Meets Primary Endpoint.
• The median percent reduction in monthly focal seizure frequency was 52.8% in the XEN1101 25 mg group, 46.4% in the XEN1101 20 mg group, and 33.2% in the XEN1101 10 mg group compared to 18.2% in the placebo group. 
• The percentage of subjects who achieved over 50% reduction in monthly focal seizures was 54.5% in the XEN1101 25 mg group, 43.1% in the XEN1101 20 mg group, and 28.3% in the XEN1101 10 mg group compared to 14.9% in the placebo group. 
• The marked reductions in seizures were associated with statistically significant improvements in overall status.
• The most common adverse events across all XEN1101 dose groups were dizziness, somnolence, fatigue, and headache.
• Price Action: XENE shares are up 10.1% at $28.49 during the premarket session on the last check Friday.